With regard to the above paper published online, I would like to underscore some points. Because of 50 years in clinical experience, I partially agree with the authors' conclusions in the joint statement from the American Diabetes Association and the European Association for the Study of Diabetes (Kahn et al., 2005) . They rightly underscore 'that too much critically important information is missing to warrant its designation as a syndrome'. In fact, nowadays clinicians 'should evaluate and treat all CVD risk factors without regard to whether a patient meets the criteria for diagnosis of the 'metabolic syndrome' (Kahn et al., 2005) .
The fact is that there are a growing number of physicians who are capable of early recognition of pre-metabolic syndrome, I discovered earlier, and after years or decades, identify the metabolic one, which always follows the former (Stagnaro-Neri et al., 2004; Stagnaro et al., 2005) . In addition, at the base alteration in these syndromes there are both parenchymal and microvascular inherited alterations in some biological systems, which parallel the former, according to my theory of Angiobiopathy, which completes Tischendorf's Angiobiotopy theory Stagnaro, 1991, 1993; Stagnaro et al., 2002 Stagnaro et al., , 2005 StagnaroNeri et al., 2004; Stagnaro, 2006) .
As a matter of fact, alterations of microvascular tissue units account for the reason that great arterial vessels and particularly microvessels show an impaired motility, that is, vasomotility and vasomotion, according to (Hammersen, 1968) (I also refer to personal web sites http://www.semeio ticabiofisica.it, Biophysical-Semeiotic Constitutions and http://semeioticabiofisica.it/microangiology) Stagnaro, 1991, 1993; Stagnaro et al., 2002 Stagnaro et al., , 2005 Stagnaro-Neri et al., 2004) . Indeed, neither all dyslipidaemics nor diabetics present metabolic syndrome, both classic and 'variant', I have described previously Stagnaro, 1991, 1993; Stagnaro-Neri et al., 2004; Stagnaro et al., 2005) .
Certainly, interventions involving lower blood pressure, glycaemia, serum cholesterol and other risk factors (such as clinically diagnosed IIR) reduce the risk of cardiovascular disease (CVD) regardless of initial levels, and decrease the risk factors as much as possible. However, my personal lengthy clinical experience has taught me that we must go beyond the known risk factors. In fact, primary prevention of the most common and dangerous human pathologies, for example, CVD, depends clearly upon easy and immediate bedside detection of individuals at 'real' risk, potentially from birth, that is, well-defined biophysical-semeiotic constitutions, assessed clinically in a quantitative way (StagnaroNeri and Stagnaro, 1993) .
In order to clinically define a particular constitution and related real risk, which does not exclude the presence of several constitutions, it is necessary to consider a present possibility of gathering biophysical-semeiotic data at the bedside. This would include the necessary biological and molecular-biological information on the various human organs, tissues and biological systems, and at the same time reveal numerous types of biophysical-semeiotic constitutions (even from the quantitative point of view).
Without any doubt, these data cannot be observed in either traditional physical or sophisticated semeiotics. On a larger scale, the latter is unable to carry molecular-biological events to clinical dimension, which represents the most original and fertile aspect of biophysical semeiotics and allows the doctor to correctly diagnose pre-metabolic and metabolic syndrome. In addition, despite the level of physical examination performed, sophisticated semeiotics are expensive, making their use on a large-scale basis unlikely. I am sure that going beyond the traditional risk factors represents a new medical 'Weltanschauung'. In addition, it would require open-minded physicians as 'peer-reviewers', although unfortunately seem harder to find in present times. 
S Stagnaro

